CJC-1295 & Ipamorelin Stack: Dosing, Results & Side Effects (2026)

Overview

The combination of CJC-1295 and Ipamorelin has become one of the most widely discussed peptide stacks in the growth hormone optimization space. These two peptides are frequently paired because they act on different receptors in the growth hormone axis, creating a complementary mechanism that produces greater GH release than either peptide used individually. CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary gland to produce and release growth hormone. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — it mimics ghrelin, the "hunger hormone" that also powerfully stimulates GH release through a separate pathway. When administered together, they amplify pulsatile growth hormone secretion while preserving the body's natural GH feedback mechanisms, which is one reason this combination is preferred over exogenous growth hormone by some clinicians. It is essential to understand that neither CJC-1295 nor Ipamorelin is FDA-approved for any clinical indication, and the evidence base consists primarily of preclinical studies and small clinical trials. This guide reviews the available scientific data, common protocols, and safety considerations. This is educational content only and does not constitute medical advice — consult a qualified healthcare provider before considering any peptide therapy.

Understanding CJC-1295: GHRH Analog Mechanism

CJC-1295 is a synthetic peptide analog of growth hormone releasing hormone (GHRH), specifically a modified version of the first 29 amino acids of GHRH (known as GRF 1-29 or Sermorelin). The key innovation in CJC-1295's design is the incorporation of amino acid substitutions at positions 2, 8, 15, and 27 of the GHRH(1-29) sequence, which confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) — the same enzyme that degrades native GLP-1 and GIP. These modifications dramatically extend the biological half-life from the minutes-long duration of native GHRH to several days for CJC-1295. CJC-1295 exists in two forms that are important to distinguish. CJC-1295 with Drug Affinity Complex (DAC) incorporates a lysine-linked maleimido group that covalently binds to serum albumin after injection, extending its effective half-life to approximately 6-8 days and resulting in sustained elevation of growth hormone and IGF-1 levels. CJC-1295 without DAC (sometimes called "Modified GRF 1-29" or "Mod GRF 1-29") lacks this albumin-binding modification and has a much shorter half-life of approximately 30 minutes, producing more acute, pulsatile GH release patterns. In the context of the CJC-1295/Ipamorelin stack, the version without DAC (Mod GRF 1-29) is more commonly used because its shorter action better mimics natural pulsatile GH release and pairs more logically with the similarly short-acting Ipamorelin. The published clinical data on CJC-1295 with DAC showed dose-dependent increases in both growth hormone and IGF-1 levels. A phase 1/2 study by Teichman et al. (2006) demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced sustained increases in mean GH concentrations for up to 6 days and elevated IGF-1 levels for 9-11 days, with a 2-10 fold increase depending on dose.

Understanding Ipamorelin: Selective GHS-R Agonist

Ipamorelin is a pentapeptide (five amino acids) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. It was developed in the late 1990s by Novo Nordisk and has been the subject of several published studies examining its pharmacology and clinical effects. What distinguishes Ipamorelin from other GHS-R agonists — such as GHRP-2, GHRP-6, and hexarelin — is its high selectivity for growth hormone release without significantly affecting other pituitary hormones or causing unwanted secondary effects. Specifically, Ipamorelin stimulates growth hormone release in a dose-dependent manner without substantially elevating cortisol (the stress hormone) or prolactin at therapeutic doses, a significant advantage over GHRP-2 and GHRP-6, which can elevate both cortisol and prolactin and also increase appetite through ghrelin-like effects. This selectivity was demonstrated in a study by Raun et al. (1998) published in the European Journal of Endocrinology, which showed that Ipamorelin produced GH release comparable to GHRP-6 but with negligible effects on ACTH (adrenocorticotropic hormone) and cortisol, even at doses up to 13 times the effective GH-releasing dose. The mechanism by which Ipamorelin stimulates GH release is distinct from CJC-1295's GHRH-mimicking action. While CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, Ipamorelin activates the GHS-R on both the pituitary gland and in the hypothalamus. In the hypothalamus, GHS-R activation stimulates the release of endogenous GHRH from GHRH neurons while simultaneously inhibiting somatostatin (the hormone that suppresses GH release). This dual hypothalamic action — increasing the GH-releasing signal while reducing the GH-inhibiting signal — creates a permissive environment for enhanced GH secretion.

The Synergy: Why CJC-1295 and Ipamorelin Are Combined

The rationale for combining CJC-1295 (Mod GRF 1-29) with Ipamorelin is rooted in the fundamental physiology of growth hormone regulation, which involves two primary signals that work in concert. Growth hormone release from the anterior pituitary is controlled by the balance between GHRH (which stimulates GH release) and somatostatin (which inhibits it). The ghrelin/GHS-R pathway acts as a third regulatory input that both amplifies the GHRH signal and suppresses somatostatin's inhibitory tone. When a GHRH analog like CJC-1295 is administered alone, it stimulates somatotroph cells to release GH, but the response is limited by the ambient somatostatin tone. Conversely, when a GHS-R agonist like Ipamorelin is administered alone, it reduces somatostatin inhibition and amplifies GHRH signaling, but the GH release is limited by the amount of endogenous GHRH available. By administering both simultaneously, you provide the direct GH-releasing signal (via CJC-1295 at the GHRH receptor) while simultaneously creating the optimal conditions for that signal to be fully expressed (via Ipamorelin's suppression of somatostatin and amplification of GHRH receptor sensitivity). Published research on the interaction between GHRH and GHS-R agonism supports this synergistic model. A study by Bowers et al. demonstrated that combining GHRH with a ghrelin mimetic produced GH release that was significantly greater than the sum of each agent's individual effect — a hallmark of true pharmacological synergy.

CJC-1295 + Ipamorelin vs. GH Secretagogue Alternatives: Comparison Table

Choosing between the CJC-1295/Ipamorelin stack and other GH optimization approaches requires understanding the tradeoffs across efficacy, side effects, dosing convenience, and cost. The table below compares the major options: | Approach | GH Release Pattern | Cortisol/Prolactin Effect | Appetite Effect | Dosing | Evidence Level | |---|---|---|---|---|---| | CJC-1295 (no DAC) + Ipamorelin | Pulsatile — physiologic | Minimal | Minimal | SC 1-3x daily | Moderate | | CJC-1295 (with DAC) | Sustained/flat | Minimal | Minimal | SC 1-2x weekly | Moderate (clinical data) | | MK-677 (Ibutamoren) | Sustained/flat | Modest elevation | Significant hunger | Oral once daily | Moderate | | GHRP-6 alone | Pulsatile | Elevated cortisol | Significant hunger | SC 2-3x daily | Moderate | | GHRP-2 alone | Pulsatile | Elevated cortisol/prolactin | Moderate hunger | SC 2-3x daily | Moderate | | Sermorelin alone | Pulsatile (shorter) | Minimal | Minimal | SC daily | Moderate | | Exogenous GH (somatropin) | Continuous (non-pulsatile) | Variable | None (direct) | Daily SC injection | Strong (FDA-approved for GHD) | For most users seeking pulsatile, physiologic GH augmentation with minimal cortisol/prolactin effects, the CJC-1295 (no DAC) + Ipamorelin combination represents the most favorable risk-benefit profile. MK-677 offers oral convenience but with different endocrine dynamics and greater appetite stimulation. Exogenous GH is more powerful but suppresses endogenous GH production and carries greater side effect risk.

Common Dosing Protocols

It is important to emphasize that neither CJC-1295 nor Ipamorelin is FDA-approved, and there are no regulatory agency-sanctioned dosing guidelines. The protocols described here are derived from published clinical research, anti-aging medicine literature, and clinical experience reported by practitioners who work with these compounds under medical supervision. The most commonly referenced protocol involves subcutaneous injection of CJC-1295 (Mod GRF 1-29) at 100 mcg combined with Ipamorelin at 100-200 mcg, administered 1-3 times daily. The typical schedule involves dosing at bedtime (to augment the natural nocturnal GH pulse), with some protocols adding a morning dose or a pre-workout dose. The bedtime dose is considered the most important because it aligns with the body's natural circadian rhythm of GH secretion — the largest physiological GH pulse occurs during the first period of slow-wave (deep) sleep, typically within the first 1-2 hours of falling asleep. Administering the peptide combination approximately 20-30 minutes before bed aims to amplify this natural pulse. For the CJC-1295 with DAC version (which has a multi-day half-life), the dosing is different: typically 2 mg (2,000 mcg) administered once or twice per week via subcutaneous injection, sometimes combined with daily Ipamorelin doses on non-CJC-DAC days. The injection is typically administered subcutaneously in the abdominal fat pad, similar to insulin injection technique, using a standard insulin syringe. Both peptides can be drawn into the same syringe and injected simultaneously. The peptides should be administered on an empty stomach or at least 1-2 hours after eating, as elevated blood glucose and insulin levels can blunt the GH response.

• Common protocol: CJC-1295 (no DAC) 100 mcg + Ipamorelin 100-200 mcg, 1-3 times daily
• Preferred timing: 20-30 minutes before bedtime to amplify natural nocturnal GH pulse
• Optional additional doses: morning (upon waking) and/or pre-workout
• Administer on an empty stomach — elevated insulin blunts GH response
• Subcutaneous injection in abdominal fat pad; both peptides can be combined in one syringe
• CJC-1295 with DAC (if used): 2 mg once or twice weekly — produces sustained rather than pulsatile GH elevation
• Cycling approaches vary: common protocols include 3-6 months on, 1-2 months off

Expected Results and Timeline

Setting realistic expectations for the CJC-1295/Ipamorelin combination requires acknowledging the significant gap between anecdotal reports and controlled clinical evidence. These peptides stimulate the body's own growth hormone production rather than providing exogenous GH, so the effects are more subtle and gradual than those seen with pharmaceutical-dose growth hormone replacement. Measurable increases in serum GH and IGF-1 levels can be detected within the first 1-2 weeks of consistent use, based on published pharmacokinetic data. However, the physiological effects that users typically seek — improved body composition, better sleep quality, enhanced recovery — develop more gradually. Improved sleep quality is often reported as one of the earliest noticeable effects, typically within the first 2-4 weeks. Users frequently describe deeper, more restorative sleep and more vivid dreaming, which is consistent with the known role of growth hormone in sleep architecture. Changes in recovery from exercise and reductions in joint discomfort are commonly reported in the 4-8 week timeframe. Body composition changes — modest reductions in body fat and improvements in lean mass — are the most frequently cited goals but also the slowest to materialize. A study on tesamorelin (an FDA-approved GHRH analog) showed approximately 5-8% reductions in visceral adipose tissue over 6 months — this provides a reasonable benchmark for what enhanced endogenous GH secretion might achieve.

• Weeks 1-2: measurable increases in serum GH and IGF-1 levels on blood work
• Weeks 2-4: improved sleep quality is often the first noticeable effect
• Weeks 4-8: enhanced recovery from exercise, potential reduction in joint discomfort
• Months 2-3: gradual body composition improvements, skin quality changes reported
• Months 3-6: most significant cumulative effects on lean mass, body fat, and overall vitality
• Individual variability is significant — age, baseline GH levels, lifestyle factors all influence results
• Effects are more subtle and gradual than exogenous GH therapy

Side Effects and Safety Considerations

The side effect profile of the CJC-1295/Ipamorelin combination is generally considered favorable compared to exogenous growth hormone administration, but the limited scope of clinical safety data requires a cautious interpretation. The most commonly reported side effects are injection site reactions (redness, mild pain, or swelling at the injection site), which are common to all subcutaneous injectable peptides and are typically mild and self-limiting. Transient flushing and warmth, particularly in the face, can occur within minutes of injection and is related to the vasodilatory effects of growth hormone release — this is usually brief (5-15 minutes) and not harmful. Water retention is a recognized effect of elevated growth hormone levels and may manifest as mild puffiness, particularly in the hands and feet. This effect is dose-dependent and typically resolves with dose reduction or discontinuation. Headache and light-headedness have been reported, particularly during the early weeks of use as the body adjusts to altered GH dynamics. Ipamorelin's selectivity profile means it does not significantly elevate cortisol or prolactin at standard doses, which avoids several side effects associated with less selective GHS-R agonists. However, theoretical long-term safety concerns exist. Chronically elevated IGF-1 levels have been associated in epidemiological studies with modestly increased risk of certain cancers, including prostate, breast, and colorectal cancer, though a causal relationship has not been definitively established. Individuals with a history of cancer or active malignancy should avoid GH secretagogues as a precaution. Effects on insulin sensitivity are complex — acute GH elevation can transiently increase insulin resistance. Anyone considering this peptide combination should undergo baseline and periodic blood work including IGF-1, fasting glucose, insulin, HbA1c, and a complete metabolic panel under the supervision of a qualified healthcare provider.

• Injection site reactions: mild redness, pain, or swelling (common, self-limiting)
• Transient flushing and warmth: occurs minutes after injection, resolves in 5-15 minutes
• Water retention: mild puffiness in hands/feet, dose-dependent, reversible
• Headache and light-headedness: typically during early weeks of use
• Ipamorelin advantage: does not significantly elevate cortisol or prolactin (unlike GHRP-2/GHRP-6)
• Long-term theoretical concerns: elevated IGF-1 and potential cancer risk, insulin resistance
• Contraindicated in active cancer or cancer history; monitor IGF-1 and metabolic markers regularly

Required Bloodwork and Monitoring Protocol

Comprehensive blood work monitoring is considered essential for anyone using GH secretagogue peptides, and baseline values should be established before starting any protocol. The primary marker is IGF-1 (insulin-like growth factor-1), which reflects integrated GH secretion over the preceding 24-48 hours and is more reliable than spot GH measurements (since GH is released in pulses and varies dramatically throughout the day). The goal for most anti-aging protocols is to achieve IGF-1 levels in the upper-normal range for the patient's age and sex — not supraphysiological levels. Metabolic markers including fasting glucose, fasting insulin, and HbA1c should be monitored because GH elevation can transiently reduce insulin sensitivity. A comprehensive metabolic panel (CMP) provides liver and kidney function assessment. Thyroid function (TSH, free T3, free T4) should be checked because GH can increase the conversion of T4 to T3. Lipid panel monitoring is appropriate as GH influences lipid metabolism. For a complete picture, some practitioners also check IGFBP-3, PSA in men (as a prostate cancer screening measure), and inflammatory markers. Baseline and follow-up blood work at 4-6 weeks, 3 months, and every 3-6 months thereafter is a common monitoring schedule. All monitoring should be supervised by a healthcare provider.

• Baseline before starting: IGF-1, fasting glucose, insulin, HbA1c, comprehensive metabolic panel, thyroid function, lipid panel
• Follow-up at 4-6 weeks: IGF-1 to confirm appropriate response (target upper-normal for age/sex)
• Every 3 months: full metabolic panel, IGF-1, glucose markers
• Men: consider PSA monitoring given IGF-1 elevation and theoretical prostate risk
• If IGF-1 exceeds age-appropriate normal range: reduce dose or frequency immediately
• Monitor blood pressure and edema trends as early warning signals for GH excess

References

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (2006) — PubMed
2. Ipamorelin, the first selective growth hormone secretagogue (1998) — PubMed
3. Synergistic interactions between GHRH and ghrelin analogs on GH release (2004) — PubMed
4. Growth hormone secretagogues: history, mechanism of action, clinical development (2000) — PubMed
5. Safety and tolerability of tesamorelin, a growth hormone-releasing factor analog, in HIV patients with excess abdominal fat (2010) — PubMed
6. Neuroendocrine and sleep EEG effects of the growth hormone secretagogue MK-677 (1997) — PubMed
7. IGF-1 and cancer risk: a meta-analysis of prospective studies (2014) — PubMed